InspireMD (NYSE:NSPR) Director Buys $18,394.25 in Stock

InspireMD, Inc. (NYSE:NSPR) Director Scott Ward purchased 15,995 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $18,394.25. Following the acquisition, the director owned 163,841 shares of the company’s stock, valued at $188,417.15. The trade was a 10.82% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

InspireMD Trading Down 0.9%

InspireMD stock traded down $0.01 during mid-day trading on Friday, hitting $1.15. The stock had a trading volume of 261,553 shares, compared to its average volume of 174,764. The stock has a 50-day simple moving average of $1.51 and a two-hundred day simple moving average of $1.75. The stock has a market capitalization of $53.93 million, a PE ratio of -1.53 and a beta of 0.82. InspireMD, Inc. has a 12 month low of $1.02 and a 12 month high of $2.93.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on NSPR. Lake Street Capital set a $4.00 price target on InspireMD in a report on Monday. Maxim Group began coverage on InspireMD in a report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price target on the stock. Loop Capital set a $5.00 price target on InspireMD in a report on Tuesday, February 24th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of InspireMD in a report on Tuesday. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, InspireMD presently has an average rating of “Buy” and an average target price of $4.50.

Institutional Investors Weigh In On InspireMD

A number of hedge funds have recently modified their holdings of the business. Rosalind Advisors Inc. raised its position in shares of InspireMD by 70.6% during the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the period. Nantahala Capital Management LLC grew its holdings in shares of InspireMD by 45.7% during the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock worth $8,137,000 after buying an additional 1,058,467 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of InspireMD by 27.9% during the fourth quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock worth $5,649,000 after buying an additional 692,247 shares in the last quarter. Orbimed Advisors LLC grew its holdings in shares of InspireMD by 46.9% during the fourth quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after buying an additional 1,000,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC grew its holdings in shares of InspireMD by 97.6% during the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock worth $5,882,000 after buying an additional 1,205,328 shares in the last quarter. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.